Shandong Aonai Biopharmaceutical Co., Ltd., a leading pet probiotics manufacturer and pet supplement supplier based in Linyi City, Shandong Province, China, has been officially certified as a drafting unit of the group standard T/CAQI 362-2023 General Rules for Probiotics in Pet Food, issued by the China Association for Quality Inspection (CAQI). The standard was published on December 15, 2023 and implemented on December 22, 2023, with the drafting unit certificate issued on January 10, 2024. This certification positions the company at the center of China's probiotic pet food standardization efforts ― a strategic category where the company also holds internationally granted patent protection.
Group standard T/CAQI 362-2023 General Rules for Probiotics in Pet Food establishes general requirements for the use of probiotics in pet food products, addressing critical aspects including probiotic strain selection, viable cell counts, product stability, labeling, and quality control. As the global demand for dog probiotics, cat probiotics, and pet probiotics continues to surge ― with "dog probiotics" alone attracting tens of thousands of monthly searches worldwide ― a unified technical standard is essential to ensure product efficacy, consistency, and consumer safety.
The standard was initiated by the China Association for Quality Inspection (CAQI), a national professional organization dedicated to quality inspection and product quality promotion. Shandong Aonai Biopharmaceutical was selected as a drafting unit based on its recognized technical expertise in probiotic pet food, demonstrated through its proprietary Dr.kalan compound probiotic technology.
The technical content of the standard addresses the key quality dimensions of probiotic pet food: the identity and source requirements of probiotic strains, minimum viable cell counts at the end of shelf life, stability under storage and processing conditions, compatibility with other feed ingredients, and truthful labeling of strain names and counts. These provisionsmatter because the probiotic market has long suffered from unclear claims ― some products advertise "high activity" without disclosing strain identity or survival conditions. The standard helps close that gap by establishing clear, verifiable technical requirements, giving pet owners and professional buyers a reliable basis for comparing products.
The company's qualification as a standard drafting unit is grounded in real technical substance:
Granted patent protection: the Dr.kalan compound probiotic has been officially granted a Dutch invention patent (No. 4000956, granted July 30, 2026, valid until February 3, 2046), confirming the novelty and inventiveness of the technology at the international level;
Deposited core strains: the product's core strains are deposited at the China General Microbiological Culture Collection Center (CGMCC, Institute of Microbiology, Chinese Academy of Sciences) under deposit numbers 10701, 13044, 17225, and 19824, ensuring strain uniqueness and traceability;
Verified performance: the patented formula achieves an intestinal colonization rate 35% higher than human-derived strains, a 24-month room-temperature shelf life with viable bacteria retention of no less than 80%, and a more than 50% improvement in intestinal problem resolution under stress conditions.
This combination of international patent protection and domestic standard-setting participation gives the company a rare dual credential in the probiotic pet food space.
For brands, distributors, and retailers building probiotic pet food lines, the company's certification as a standard drafting unit offers concrete advantages:
Standards-first production: the company produces in accordance with the same national group standard it helped draft, ensuring regulatory alignment and quality consistency;
Proven strain technology: partners gain access to patented, CGMCC-deposited strain technology rather than generic formulations;
Flexible cooperation models: the Dr.kalan probiotic technology is available through OEM/ODM, private label, bulk supply, and custom formula programs, including private label dog probiotics and probiotic powder for petsproduction;
Factory-direct value: as a factory-direct pet probiotic manufacturer, the company combines standard-setting credibility with competitive bulk pricing for global buyers.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and pet supplement supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patents and patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
As a certified drafting unit of T/CAQI 362-2023, Shandong Aonai Biopharmaceutical will continue to advance the science and standardization of pet probiotics, delivering safe and effective gut health solutions to pets and pet parents worldwide.
EN
